APA

Chopra A., Chandrashekara S., Iyer R., Rajasekhar L., Shetty N., Veeravalli S. M., Ghosh A., Merchant M., Oak J., Londhey V., Barve A., Ramakrishnan M. S. & Montero E. (20170116). Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study. : Clinical rheumatology.

Chicago

Chopra Arvind, Chandrashekara S, Iyer Rajgopalan, Rajasekhar Liza, Shetty Naresh, Veeravalli Sarathchandra Mouli, Ghosh Alakendu, Merchant Mrugank, Oak Jyotsna, Londhey Vikram, Barve Abhijit, Ramakrishnan M S and Montero Enrique. 20170116. Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study. : Clinical rheumatology.

Harvard

Chopra A., Chandrashekara S., Iyer R., Rajasekhar L., Shetty N., Veeravalli S. M., Ghosh A., Merchant M., Oak J., Londhey V., Barve A., Ramakrishnan M. S. and Montero E. (20170116). Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study. : Clinical rheumatology.

MLA

Chopra Arvind, Chandrashekara S, Iyer Rajgopalan, Rajasekhar Liza, Shetty Naresh, Veeravalli Sarathchandra Mouli, Ghosh Alakendu, Merchant Mrugank, Oak Jyotsna, Londhey Vikram, Barve Abhijit, Ramakrishnan M S and Montero Enrique. Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study. : Clinical rheumatology. 20170116.